Cantitate/Preț
Produs

Cognitive Enhancement: Handbook of Experimental Pharmacology, cartea 228

Editat de Kathleen M. Kantak, Joseph G. Wettstein
en Limba Engleză Hardback – 29 mai 2015
This book highlights the behavioral and neurobiological issues relevant for drug development, reviews evidence for an innovative approach for drug discovery and presents perspectives on multiple special topics ranging from therapeutic drug use in children, emerging technologies and non-pharmacological approaches to cognitive enhancement.
Citește tot Restrânge

Toate formatele și edițiile

Toate formatele și edițiile Preț Express
Paperback (1) 131438 lei  39-44 zile
  Springer International Publishing – 12 oct 2016 131438 lei  39-44 zile
Hardback (1) 137277 lei  6-8 săpt.
  Springer International Publishing – 29 mai 2015 137277 lei  6-8 săpt.

Din seria Handbook of Experimental Pharmacology

Preț: 137277 lei

Preț vechi: 144502 lei
-5% Nou

Puncte Express: 2059

Preț estimativ în valută:
26273 27717$ 21895£

Carte tipărită la comandă

Livrare economică 02-16 ianuarie 25

Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9783319165219
ISBN-10: 3319165216
Pagini: 450
Ilustrații: VIII, 470 p. 30 illus., 24 illus. in color.
Dimensiuni: 155 x 235 x 25 mm
Greutate: 0.84 kg
Ediția:2015
Editura: Springer International Publishing
Colecția Springer
Seria Handbook of Experimental Pharmacology

Locul publicării:Cham, Switzerland

Public țintă

Research

Cuprins

Preface.- Part 1. Basic Approaches and Perspectives.- Part 2. Cognitive Domains for Pharmacological Intervention: Implications for Neuropsychiatric and Neurological Illnesses.- Part 3. Developmental Disorders, Emerging Technologies and Ethical Considerations.

Caracteristici

Emphasizes individual cognitive domains, cutting across disease and disorder, with a perspective on the pharmacology for each Maximizes insights into evolving themes that will bring cognitive research into a new era Gives a broad overview on unique cognitive domains and the potential to treat with drugs the impairments in individual domains rather than in individual neurologic diseases or psychiatric disorders